# ORIC Pharmaceuticals

Source: https://onco.cc/companies/oric-pharmaceuticals/  
OnCo record `oric-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ORIC Pharmaceuticals develops pills designed to beat the ways cancers resist treatment. One blocks a gene-silencing complex in prostate cancer; the other targets mutated EGFR and HER2 in lung cancer and can reach the brain.

## Summary

ORIC Pharmaceuticals is a South San Francisco clinical-stage oncology company focused on mechanisms of therapeutic resistance. Rinzimetostat (ORIC-944) is a potent, selective allosteric inhibitor of PRC2 acting through the EED subunit rather than EZH2, designed for better drug properties and to avoid EZH1 bypass or EZH2 mutation; it is in development for prostate cancer in combination with androgen receptor pathway inhibitors. Enozertinib (ORIC-114) is a brain-penetrant inhibitor of EGFR exon 20 insertion and other atypical EGFR and HER2 alterations in non-small cell lung cancer, including a clinical collaboration with Johnson & Johnson combining it with subcutaneous amivantamab in first-line EGFR exon 20 NSCLC. ORIC completed its Nasdaq IPO in April 2020 with gross proceeds of 138 million US dollars.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: South San Francisco, CA
- Type: biotech
- Website: https://oricpharma.com/
- Ticker: ORIC

## Notes

- The ezh2 tag denotes PRC2 targeting via EED (not EZH2 itself); the androgen-receptor tag reflects the combination strategy with AR pathway inhibitors rather than a direct AR drug. Founding year and current trial phases not sourced.

## Sources

- Official website: https://oricpharma.com/
- Pipeline: https://oricpharma.com/pipeline/
- IPO closing press release (SEC exhibit): https://www.sec.gov/Archives/edgar/data/1796280/000156459020019302/oric-ex991_68.htm

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Epigenetic & Transcriptional Therapy](https://onco.cc/fronts/epigenetics/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/), [EGFR](https://onco.cc/targets/egfr/), [EZH2](https://onco.cc/targets/ezh2/)
- drugs: [Rinzimetostat](https://onco.cc/drugs/rinzimetostat/)
- trials: [A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)](https://onco.cc/trials/himalayas-1/), [Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration](https://onco.cc/trials/nct05315700/)

---
JSON: https://onco.cc/api/v1/entities/oric-pharmaceuticals.json